Proceedings of the American Thoracic Society Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

The Proceedings of the American Thoracic Society 3:571-576 (2006)
© 2006 The American Thoracic Society
doi: 10.1513/pats.200605-113LR
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Galiè, N.
Right arrow Articles by Kim, N. H. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Galiè, N.
Right arrow Articles by Kim, N. H. S.

Pulmonary Microvascular Disease in Chronic Thromboembolic Pulmonary Hypertension

Nazzareno Galiè and Nick H. S. Kim

Institute of Cardiology, University of Bologna, Bologna, Italy; and Division of Pulmonary and Critical Care Medicine, University of California, San Diego, La Jolla, California

Correspondence and requests for reprints should be addressed to Nazzareno Galiè, M.D., Ospedale S. Orsola, Istituto di Malattie dell'Apparato Cardiovascolare, Università di Bologna, Via Massarenti, 9, 40138 Bologna, Italy. E-mail: nazzareno.galie{at}unibo.it

ABSTRACT

Distal, small-vessel vasculopathy is generally considered a major contributor to the progression of pulmonary hypertension (PH) as chronic thromboembolic pulmonary hypertension (CTEPH) develops over time and is a major determinant of postoperative outcome after pulmonary endarterectomy (PEA). The pathogenesis and natural history of microvascular disease in CTEPH remain uncharacterized. Mechanisms for significant distal disease may involve the following processes: (1) predominant obstructions of "small" subsegmental elastic pulmonary arteries, (2) classical pulmonary arteriopathy of small muscular arteries and arterioles distal to nonobstructed vessels, (3) pulmonary arteriopathy of small muscular arteries and arterioles distal to totally or partially obstructed vessels. Patients in whom obstructed vessels are mainly subsegmental are considered poor surgical candidates. Distal pulmonary vasculopathy in both the occluded and nonoccluded pulmonary vascular bed is characterized by lesions considered typical for idiopathic pulmonary arterial hypertension, including plexiform lesions. The pathogenesis and time course of these vascular lesions remain unclear, but may involve endothelial and/or platelet production and release of mediators and/or altered pulmonary blood flow. The reciprocal contribution of large-vessel (operable) and small-vessel lesions in CTEPH is crucial for the indication and results of PEA. A combination of investigations is used to identify the extent of small-vessel disease, including right-heart catheterization, perfusion lung scan, multidetector spiral computed tomography, pulmonary angiography, and pulmonary arterial occlusion wave-form analysis. Preliminary evidence suggests that medical therapy may provide hemodynamic and clinical benefits for patients in whom PEA cannot be applied, in those who have persistent postoperative PH, or in selected patients with advanced preoperative hemodynamic changes.

Key Words: hypertension • pulmonary • pulmonary embolism.

Pulmonary endarterectomy (PEA) is the accepted treatment of choice for patients with chronic thromboembolic pulmonary hypertension (CTEPH). However, PEA can only relieve the portion of pulmonary vascular resistance (PVR) that is accessible and amenable to surgical intervention, and outcomes are poor in many cases where chronic thromboembolic obstructions lie in distal, subsegmental arteries (1–4). As a result, CTEPH is considered inoperable in 10 to 30% of cases—for instance, when a high PVR is present without evidence of proportional gross organized thromboembolic pathology on angiogram. Despite great advances in surgical success with PEA, postoperative pulmonary hypertension (PH) is seen in 10% of cases, and surgery cannot be considered curative in these cases (5). Indeed, nearly three-quarters of early postoperative and half of long-term deaths have been attributed to persistent PH, making this the main cause of post-PEA mortality (4).

The precise mechanisms and natural history of microvascular disease in CTEPH remain speculative (6, 7). Nevertheless, it is believed that a substantial component of persistent postoperative PH is related to distal pulmonary vasculopathy in small precapillary vessels both in the occluded and nonoccluded pulmonary vascular bed (2). Histopathologic studies of microvascular changes in CTEPH have identified vascular lesions similar to those seen in idiopathic pulmonary arterial hypertension (IPAH) and Eisenmenger's syndrome (8–10). Although acute pulmonary embolism is generally accepted as the main initiating event in CTEPH, small-vessel arteriopathy is believed to appear and worsen later in the course of disease, and to contribute to the progression of hemodynamic and symptomatic decline (6, 7, 11). This can explain progressive PH and right ventricular dysfunction in the absence of recurrent pulmonary embolism (PE), as observed in patients with CTEPH (12).

Research to further characterize the natural history of small-vessel disease and to improve preoperative screening and identification of high-risk and inoperable patients may allow more targeted or earlier treatment, and could improve therapeutic outcome. This article describes the types, possible pathophysiology, and impact of microvascular disease in CTEPH, and suggests possible directions for future research.

MICROVASCULAR DISEASE AND POSTOPERATIVE OUTCOME

CTEPH is currently classified intraoperatively according to the general scheme summarized in Table 1, which is based on extensive experience and postsurgery review (1, 13). As covered in detail elsewhere (14), the extent and type of microvascular disease in CTEPH have a strong influence on the likelihood of a successful outcome in PEA. Patients with CTEPH categories I and II who display significant and accessible organized thromboemboli in proximal pulmonary vessels are likely to benefit most from PEA. In general, only selected patients with type III CTEPH (with disease in distal segmental or subsegmental arteries) can be successfully operated on, and patients with type IV disease (isolated distal vasculopathy) have no indication for PEA (1, 13).


View this table:
[in this window]
[in a new window]
  		TABLE 1. POSTOPERATIVE PULMONARY CLASSIFICATION OF CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION

 
More pronounced microvascular disease contributes to a greater preoperative PVR, which has been shown to be associated with greater postoperative mortality (2). Pulmonary hypertension persists in patients with significant microvascular disease despite removal of proximal material. In the largest case series reported so far (n = 1,500), Jamieson and colleagues (4) established that persistent postoperative PH was the most important predictor of mortality after PEA surgery.

MECHANISMS FOR SMALL-VESSEL DISTAL DISEASE

Mechanisms for distal small-vessel pulmonary disease seen in CTEPH can be broadly categorized into three processes (Table 2), which may occur alone or in combination: (1) obstructions of small subsegmental elastic arteries, (2) classical pulmonary arteriopathy in small muscular arteries and arterioles distal to nonobstructed elastic pulmonary arteries, and (3) arteriopathy in small muscular arteries and arterioles distal to obstructed elastic pulmonary arteries.


View this table:
[in this window]
[in a new window]
  		TABLE 2. POSSIBLE MECHANISMS CONTRIBUTING TO DISTAL INOPERABLE MICROVASCULAR DISEASE IN CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION

 
Figure 1 shows obstructions of small, elastic, subsegmental arteries visualized by pulmonary angiography, and Figure 2A represents the histopathologic appearance of such lesions. In the large analysis of PEA data reported by Jamieson and coworkers (4), only a minority of patients showed distal vasculopathy restricted to subsegmental elastic arteries in the absence of significant proximal pathology (Table 1). On the basis of pathologic evidence, it is not clear if patients displaying such changes represent an extreme of the spectrum of CTEPH or if they should be considered as having IPAH with additional local subsegmental thrombosis. Patients of this type are considered poor candidates for surgical intervention due to the less accessible location of obstructed vessels. Although high PVR is not a contraindication to PEA, preoperative PVR has been consistently associated with operative mortality (2), and patients with additional risk factors, such as age or cardiopulmonary comorbidity, are considered to represent too high a risk for surgical candidacy.


Figure 1
View larger version (86K):
[in this window]
[in a new window]
  		Figure 1. Pulmonary angiography of patients with chronic thromboembolic pulmonary hypertension (CTEPH) showing distal pulmonary disease. Traditional pulmonary angiography in anteroposterior view with two selective injections of contrast medium in the right (A) and left (B) pulmonary arteries: multiple stenoses and obstructions in subsegmental elastic pulmonary arteries are shown (arrows).

 

Figure 2
View larger version (67K):
[in this window]
[in a new window]
  		Figure 2. Schematic representation of three mechanisms of small-vessel disease in CTEPH. (A) Obstructions of small, elastic, subsegmental arteries not amenable to surgical treatment; (B) pulmonary arteriopathy in small muscular arteries and arterioles distal to nonobstructed elastic vessels (medial thickening, intimal proliferation, and plexiform and colander lesions are shown); (C) pulmonary arteriopathy in small muscular arteries and arterioles distal to obstructed large elastic vessels (virtually identical changes as in B).

 
Figure 2B shows the histopathologic appearance of classical pulmonary arteriopathy in small muscular arteries and arterioles distal to nonobstructed elastic vessels. Moser and Braunwald (15) were first to observe a "two-compartment pulmonary vascular bed" in CTEPH, describing small muscular pulmonary arteries distal to open elastic arteries that show marked structural changes of chronic PH; they also reported a relatively normal morphology in vascular elements distal to obliterated segments, which had not been exposed to high pressure and shear stress. In contrast, in a study with a series of lung biopsies and autopsies in over 30 patients with CTEPH, Moser and Bloor (8) showed that pulmonary hypertensive changes also occurred distally to open vessels as well as in small nonelastic arteries in lung regions distal to completely or partially obstructed vessels.

Figure 2C shows the histopathologic appearance of arteriopathy in areas distal to partially or totally obstructed elastic vessels (virtually identical to that observed distally to open vessels). Data from animal models with pulmonary artery ligation suggest that postobstructive arteriopathy may be related to development of precapillary bronchial-to-pulmonary vascular anastomoses, pulmonary arterial remodeling, and abnormal pulmonary artery vascular reactivity with pulmonary endothelial dysfunction (2, 16). Recent histopathologic evidence suggests that, in advanced CTEPH, such distal vasculopathy affects areas distal to obstructed pulmonary vessels more than areas distal to nonobstructed vessels (10).

RELEVANCE OF HISTOPATHOLOGIC FINDINGS IN CTEPH

Moser and Bloor (8) conducted the first comprehensive and systematic analysis of histopathology of small pulmonary arteries of patients with an established diagnosis of CTEPH, and concluded that, in general, patients with CTEPH displayed a full range of distal histopathologic changes indicating advanced vessel remodeling, including plexiform lesions typical of all forms of pulmonary arterial hypertension (PAH). In fact, smooth muscular hypertrophy, intimal proliferation-fibrosis, and plexogenic lesions are characteristically seen in IPAH (17–19) as well as in PAH associated with congenital or acquired conditions (20, 21). It was thus proposed that such lesions most likely represent the nonspecific effect of chronic PH on exposed (nonoccluded) areas of the vasculature.

Plexogenic lesions are now regarded as a hallmark of obstructive intimal remodeling associated with severe PAH. In a study of lungs removed at autopsy or explantation (15 cases of IPAH, 22 cases of CTEPH, 8 cases of Eisenmenger's syndrome, and 3 cases of PH due to other causes), Yi and coworkers (10) demonstrated prominent obstructive intimal thickening and formation of plexiform lesions. The pattern of lesions in CTEPH was similar to that seen in Takayasu's arteritis (Figure 3A). Lesions were seen primarily at the level of small arteries and arterioles in IPAH (Figure 3B). This latter finding supports the proposed natural history of the disease whereby endothelial damage is initiated at these locations, followed by intimal and medial proliferation and luminal obstruction in the damaged arteries (10, 22). In contrast, similar vessels in lungs mainly from patients with severe CTEPH (and hence, with more pronounced small-vessel involvement) showed significantly less intimal thickening than in IPAH (Figure 3B). This may be due to relatively nonuniform distribution of small-vessel pathology in CTEPH compared with IPAH. The scleroderma pattern was intermediate between IPAH and CTEPH (10).


Figure 3
View larger version (11K):
[in this window]
[in a new window]
  		Figure 3. Distribution of obstructive intimal lesions in different pulmonary vascular diseases. (A) Distribution of intimal thickening in CTEPH versus Takayasu's arteritis; (B) distribution of intimal lesions in CTEPH versus idiopathic pulmonary arterial hypertension (IPAH) and scleroderma-associated PAH; (C) distribution of pulmonary artery external diameters in CTEPH versus IPAH and Eisenmenger's syndrome. PPH = primary pulmonary hypertension. Adapted by permission from Reference 10.

 
As shown in Figure 3C, patterns of intimal thickening were mirrored in the occurrence of well-formed plexiform lesions, where lesions were generally associated with vessels of smaller diameter in IPAH (mean ± SEM, 79 ± 6.1 µm) compared with CTEPH (149.5 ± 11.4 µm) and significantly smaller versus those in Eisenmenger's syndrome (209 ± 17.6 µm) (10). Overall, Yi and coworkers concluded that the degree and distribution of arteriopathy in CTEPH differ from that seen in IPAH, but it is questionable whether CTEPH could be differentiated from IPAH on the basis of histopathologic evidence alone.

The functional significance of plexogenic lesions in CTEPH remains unclear. No studies have so far established a firm relationship between the extent or type of small-vessel lesions and either the course of disease or treatment outcome in PH of different origins. Moser and Bloor (8) demonstrated that patients with plexiform lesions in small pulmonary arteries showed functional and hemodynamic improvements after PEA that paralleled those in patients without them. In addition, the profile of hypertensive lesions seen in CTEPH does not appear to relate to preoperative hemodynamic values, symptom duration, or patient age. However, Yi and coworkers (10) showed that 5 in 22 patients with well-formed plexiform lesions, and three cases with plexiform-like lesions signaling some intimal proliferation, failed to show dramatic hemodynamic improvement despite successful PEA intervention. This suggests that distal plexiform pathology was likely a major contributor to their persistent PH.

Arbustini and coworkers (23) showed differences in the composition of arterial plaques seen in IPAH or "secondary plexogenic" hypertension (Eisenmenger's syndrome), compared with those seen in CTEPH. Whether this indicates any important difference in pathogenetic mechanisms is yet to be established, but the authors suggested that thrombotic material may play a crucial role in the formation of plaques seen in CTEPH, whereas fibrous neointimal plaque formation involving foam cells and lymphocytes was a likely contributor to IPAH plaque pathology (23).

An important finding from histopathologic studies is that a substantial proportion of PH in CTEPH may be related to vasculopathy not only in nonoccluded distal pulmonary vascular beds but also in those served by occluded proximal vessels (2). As discussed later, this suggests a possible role for a number of vascular mediating factors. Early autopsy studies showed characteristic vascular lesions in lung regions distal to completely obstructed and partially obstructed proximal vessels, as well as in regions served by open proximal vessels (which are exposed to PH) (8, 24). Yi and colleagues (10) reported potentially greater involvement in obstructed than in unobstructed areas in CTEPH lung, compared with relatively uniform involvement seen in lung sections from IPAH (10). Similar findings have been reported in animal models of CTEPH (2, 25, 26). Studies with partial or total pulmonary vascular obstruction by pulmonary artery ligation (in comparison with nonligated contralateral lung) consistently show features such as arterial muscular hypertrophy, peripheral muscularization, intimal fibromuscular proliferation, and adventitial thickening in lung areas distal to occluded proximal vessels, which are also seen in humans with CTEPH (8, 25, 27).

POSSIBLE PATHOGENETIC MECHANISMS

The pathogenesis of microvascular disease in CTEPH has yet to be characterized, but may share some mechanisms with PAH. In terms of the thrombotic pathology, abnormalities in the clotting cascade, endothelial cells, or platelets may contribute to a prothrombotic environment, particularly in nonoccluded areas. There is biological evidence that intravascular coagulation is a continuous process in a number of forms of PH (2, 28), although it is not known whether this results from genetic predisposing factors or endothelial/platelet dysfunction secondary to pulmonary vascular injury (29, 30). Studies of plasminogen activator-inhibitor 1 (PAI-1) alterations have provided some evidence of a molecular basis for the promotion of in situ thrombosis and stabilization of vascular thrombi in CTEPH (30, 31). However, the bulk of current evidence to date does not indicate a significant role for traditional prothrombotic factors such as antithrombin, protein S, or protein C deficiencies, or altered fibrinolytic pathways in CTEPH pathogenesis (2, 30, 32). It is suggested that the core of the pathologic process in CTEPH is not only related to thrombus formation but that it is also mainly linked to disturbed thrombus resolution (28, 33).

Endothelial dysfunction may occur in small muscular arteries distal to nonobstructed pulmonary elastic vessels, but the degree and mechanisms of endothelial dysfunction as a contributor to PH in these areas are unclear (2, 7, 10). Endothelium actively participates at a number of points in the thrombotic process (28). As covered in detail elsewhere (30), humoral markers that have so far been linked with CTEPH include anticardiolipin antibodies—a known risk factor for venous thromboembolism (34)—elevated factor VIII (29, 35), and monocyte chemoattractant protein 1 (36). Of these, only anticardiolipin antibodies are considered as a possible specific marker for CTEPH (2). The release of humoral mediating factors from endothelial cells may be stimulated by the disturbed blood flow (proximal obstruction, bronchial-to-pulmonary circulation anastomoses) in the vascular bed distal to obstructed vessels in some, as yet, unknown way.

Finally, studies indicate that impairment of nitric oxide function and endothelin-mediated vascular remodeling are possible contributory mechanisms to altered small-vessel morphology in areas distal to occluded vessels in CTEPH as well as in severe PH (16, 37, 38). Reesink and colleagues (39) identified relationships between endothelin-1 and hemodynamic parameters in CTEPH, suggesting a possible role of this mediator in the pathobiology of small-vessel disease.

CLINICAL, HEMODYNAMIC, AND IMAGING FINDINGS INDICATING MICROVASCULAR DISEASE

At least 40% of the proximal pulmonary vascular bed is obstructed in the majority of patients with CTEPH and, in addition to the effect of recurrent thromboembolism or in situ thrombosis, a number of lines of clinical evidence indicate that progressive worsening is contributed by remodeling in the small distal pulmonary arteries in the open vascular bed: (1) low correlation between the extent of central obstruction visible on pulmonary angiography and the degree of PH (2), (2) progressive PH in the absence of recurrent thromboemboli (9), (3) evidence of redistribution of pulmonary blood flow from nonoccluded to newly endarterectomized areas after PEA (vascular steal phenomenon) (8), and (4) persistent PH despite successful PEA in approximately 10 to 30% of patients (2). Clinical consequences of microvascular disease include poor surgical candidacy or outcome, response to treatments developed for PAH, and the need for appropriate methods of detection and assessment.

Risk and outcome assessments need standardization for surgical intervention in CTEPH and, as addressed elsewhere (14), evidence indicates that a more thorough preoperative appraisal of distal disease is vital for optimizing outcome. For example, preoperative PVR is a crucial factor to consider in assessing PEA candidacy as it can be used to identify high-risk patients (2). It is generally accepted that a high PVR without parallel evidence of substantial proximal obstructive changes suggests significant distal vasculopathy and greater chance of an unsuccessful postsurgery outcome (4). Because persistent PH has some degree of reversibility, it has been suggested that advanced vasculopathy can be avoided in some patients by earlier diagnosis of CTEPH and PEA intervention. However, this would require a standardized system for preoperative classification of surgical candidates that takes the degree and type of microvascular disease into account.

We therefore need to shift current focus from assessments of the obvious large-vessel component of CTEPH to the equally relevant small-vessel contribution. A number of techniques may be useful in achieving this (Table 3) (14, 40). In particular, the pulmonary artery occlusion technique may become increasingly useful for the partitioning of PVR into an arterial segment and arteriole–venous segment, and for the determination of an effective pulmonary precapillary pressure (41, 42). This could help in defining mortality risk based on upstream versus downstream vascular resistance due to distal disease (43). However, further experience and validation are required to standardize this method.


View this table:
[in this window]
[in a new window]
  		TABLE 3. PREOPERATIVE ASSESSMENTS ENABLING QUANTIFICATION OF MICROVASCULAR DISEASE IN CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION AND CATEGORIZATION OF SUBTYPES

 
Pulmonary V/Q scintigraphy is an important first step in spotting any imbalance between the magnitude of perfusion defects and PVR, although it can underestimate the actual degree of vascular obstruction. Traditional pulmonary angiography is the current "gold standard" diagnostic imaging technique for CTEPH as it allows visualization of proximal as well as distal pathology in elastic pulmonary arteries, allowing an assessment of surgical accessibility. However, multidetector spiral computed tomography in combination with traditional angiography is likely to represent the future standard for imaging as it allows clear detection of obstructions right down to the subsegmental level (40) as well as of the thickness of proximal pulmonary artery wall (which is an important technical detail for planning surgery). The comparison between the increase of the PVR (as assessed by right-heart catheterization) and the extent and location of obstructions along the elastic pulmonary arterial tree can give an estimate of the existing small-vessel vasculopathy in areas distal to open arteries. In contrast, the assessment of the degree of vasculopathy in areas distal to occluded vessels is currently an unresolved challenge.

FUTURE RESEARCH AIMS

An important future aim in research on the natural history of CTEPH is to characterize the time course over which hypertensive microvascular changes develop. We need to ascertain whether specific types of small-artery lesions predominate at certain locations or under certain conditions and we need to establish why the same pathologic changes occur in areas that are affected by high pressure as in those that are not.

Microvascular disease in CTEPH also presents a number of challenges to overall disease management. Identification of poor surgical candidacy and/or likelihood of poor surgical outcomes is vital in optimizing PEA outcome, as is the recognition of screening methods for early detection. Further research on how multidisciplinary care can be applied and how potential pharmacotherapies can be best used, alongside or as an alternative to surgical intervention, is vital (44, 45). For instance, preliminary evidence suggests that medical therapy may provide hemodynamic and clinical status benefits for patients in whom PEA cannot be applied, in those who have persistent postoperative PH, or in selected patients with unstable preoperative hemodynamics or other conditions causing unacceptable risk from PEA intervention (44, 46, 47). However, the precise role of medical therapies in the global treatment strategy of CTEPH has yet to be fully clarified, including type of medications, doses, and timing for initiation.

CONCLUSIONS

Pulmonary microvascular disease associated with CTEPH is an important consideration in optimizing patient care and subsequent clinical outcome. Its pathogenesis remains unclear, and further research is required to define mechanisms related to persistent postoperative PH and its association with known operative CTEPH subtypes. Common, agreed-upon criteria for nonoperability due to distal disease are required and, based on future studies, will likely need to be stratified according to the type of microvascular pathology present (2). This requires that definitive inclusion criteria be incorporated in clinical trials. Further formal randomized trials will be valuable in helping to define better the role of medical therapy in CTEPH, particularly in patients with significant microvascular disease.

FOOTNOTES

Conflict of Interest Statement: N.G. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. N.H.S.K. has received consultancy and speaker's fees from Actelion ($38,000), Encysive ($2,000), Cotherix ($1,500), and Schering ($2,000).

(Received in original form May 10, 2006; accepted in final form June 27, 2006)

REFERENCES

  1. Jamieson SW, Kapelanski DP. Pulmonary endarterectomy. Curr Probl Surg 2000;37:165–252.[CrossRef][Medline]
  2. Dartevelle P, Fadel E, Mussot S, Chapelier A, Herve P, de Perrot M, Cerrina J, Ladurie FL, Lehouerou D, Humbert M, et al. Chronic thromboembolic pulmonary hypertension. Eur Respir J 2004;23:637–648.[Abstract/Free Full Text]
  3. Archibald CJ, Auger WR, Fedullo PF, Channick RN, Kerr KM, Jamieson SW, Kapelanski DP, Watt CN, Moser KM. Long-term outcome after pulmonary thromboendarterectomy. Am J Respir Crit Care Med 1999;160:523–528.[Abstract/Free Full Text]
  4. Jamieson SW, Kapelanski DP, Sakakibara N, Manecke GR, Thistlethwaite PA, Kerr KM, Channick RN, Fedullo PF, Auger WR. Pulmonary endarterectomy: experience and lessons learned in 1,500 cases. Ann Thorac Surg 2003;76:1457–1462.[Abstract/Free Full Text]
  5. Fedullo PF, Auger WR, Channick RN, Kerr KM, Rubin LJ. Chronic thromboembolic pulmonary hypertension. Clin Chest Med 2001;22: 561–581.[CrossRef][Medline]
  6. Fedullo PF, Rubin LJ, Kerr KM, Auger WR, Channick RN. The natural history of acute and chronic thromboembolic disease: the search for the missing link. Eur Respir J 2000;15:435–437.[CrossRef][Medline]
  7. Hoeper MM, Mayer E, Simonneau G, Rubin L. Chronic thromboembolic pulmonary hypertension. Circulation 2006;113:2011–2020.[Free Full Text]
  8. Moser KM, Bloor CM. Pulmonary vascular lesions occurring in patients with chronic major vessel thromboembolic pulmonary hypertension. Chest 1993;103:685–692.[Abstract/Free Full Text]
  9. Azarian R, Wartski M, Collignon MA, Parent F, Herve P, Sors H, Simonneau G. Lung perfusion scans and hemodynamics in acute and chronic pulmonary embolism. J Nucl Med 1997;38:980–983.[Abstract/Free Full Text]
  10. Yi ES, Kim H, Ahn H, Strother J, Morris T, Masliah E, Hansen LA, Park K, Friedman PJ. Distribution of obstructive intimal lesions and their cellular phenotypes in chronic pulmonary hypertension: a morphometric and immunohistochemical study. Am J Respir Crit Care Med 2000;162:1577–1586.[Abstract/Free Full Text]
  11. Egermayer P, Peacock AJ. Is pulmonary embolism a common cause of chronic pulmonary hypertension? Limitations of the embolic hypothesis. Eur Respir J 2000;15:440–448.[Abstract]
  12. Moser KM, Auger WR, Fedullo PF, Jamieson SW. Chronic thromboembolic pulmonary hypertension: clinical picture and surgical treatment. Eur Respir J 1992;5:334–342.[Abstract]
  13. Thistlethwaite PA, Mo M, Madani MM, Deutsch R, Blanchard D, Kapelanski DP, Jamieson SW. Operative classification of thromboembolic disease determines outcome after pulmonary endarterectomy. J Thorac Cardiovasc Surg 2002;124:1203–1211.[Abstract/Free Full Text]
  14. Kim NHS. Assessment of operability in chronic thromboembolic pulmonary hypertension. Proc Am Thorac Soc 2006;3:584–588.[Abstract/Free Full Text]
  15. Moser KM, Braunwald NS. Successful surgical intervention in severe chronic thromboembolic pulmonary hypertension. Chest 1973;64: 29–35.[Abstract/Free Full Text]
  16. Fadel E, Mazmanian GM, Baudet B, Detruit H, Verhoye JP, Cron J, Fattal S, Dartevelle P, Herve P. Endothelial nitric oxide synthase function in pig lung after chronic pulmonary artery obstruction. Am J Respir Crit Care Med 2000;162:1429–1434.[Abstract/Free Full Text]
  17. Heath D, Smith P, Gosney J, Mulcahy D, Fox K, Yacoub M, Harris P. The pathology of the early and late stages of primary pulmonary hypertension. Br Heart J 1987;58:204–213.[Abstract/Free Full Text]
  18. Smith P, Heath D, Yacoub M, Madden B, Caslin A, Gosney J. The ultrastructure of plexogenic pulmonary arteriopathy. J Pathol 1990;160:111–121.[CrossRef][Medline]
  19. Pietra GG, Capron F, Stewart S, Leone O, Humbert M, Robbins IM, Reid LM, Tuder RM. Pathologic assessment of vasculopathies in pulmonary hypertension. J Am Coll Cardiol 2004;43:S25–S32.[CrossRef]
  20. Wagenvoort CA. Lung biopsies and pulmonary vascular disease. In: Weir EK, Reeves JT, editors. Pulmonary hypertension. Mount Kisco, NY: Futura Publishing Co; 1984. pp. 393–438.
  21. Reid LM. Structure and function in pulmonary hypertension: new perceptions. Chest 1986;89:279–288.[Free Full Text]
  22. Fishman AP. The pulmonary circulation. In: Fishman AP, Elias JA, Fishman JA, Grippi, MA, Kaiser LR, Senior RM, editors. Pulmonary diseases and disorders, 3rd ed. New York: McGraw-Hill; 1998. pp. 1233–1250.
  23. Arbustini E, Morbini P, D'Armini AM, Repetto A, Minzioni G, Piovella F, Vigano M, Tavazzi L. Plaque composition in plexogenic and thromboembolic pulmonary hypertension: the critical role of thrombotic material in pultaceous core formation. Heart 2002;88:177–182.[Abstract/Free Full Text]
  24. Anderson EG, Simon G, Reid L. Primary and thromboembolic pulmonary hypertension: and quantitative pathological study. J Pathol 1972;110:273–293.[CrossRef]
  25. Fadel E, Michel RP, Eddahibi S, Bernatchez R, Mazmanian GM, Baudet B, Dartevelle P, Herve P. Regression of postobstructive vasculopathy after revascularization of chronically obstructed pulmonary artery. J Thorac Cardiovasc Surg 2004;127:1009–1017.[Abstract/Free Full Text]
  26. Kim H, Yung GL, Marsh JJ, Konopka RG, Pedersen CA, Chiles PG, Morris TA, Channick RN. Pulmonary vascular remodeling distal to pulmonary artery ligation is accompanied by upregulation of endothelin receptors and nitric oxide synthase. Exp Lung Res 2000;26:287–301.[CrossRef][Medline]
  27. Hirsch AM, Moser KM, Auger WR, Channick RN, Fedullo PF. Unilateral pulmonary artery thrombotic occlusion: is distal arteriopathy a consequence? Am J Respir Crit Care Med 1996;154:491–496.[Abstract]
  28. Chaouat A, Weitzenblum E, Higenbottam T. The role of thrombosis in severe pulmonary hypertension. Eur Respir J 1996;9:356–363.[Abstract]
  29. Wolf M, Boyer-Neumann C, Parent F, Eschwege V, Jaillet H, Meyer D, Simonneau G. Thrombotic risk factors in pulmonary hypertension. Eur Respir J 2000;15:395–399.[Abstract]
  30. Lang IM, Kerr K. Risk factors for CTEPH. Proc Am Thorac Soc 2006; 3:568–570.[Abstract/Free Full Text]
  31. Lang IM, Marsh JJ, Olman MA, Moser KM, Schleef RR. Parallel analysis of tissue-type plasminogen activator and type 1 plasminogen activator inhibitor in plasma and endothelial cells derived from patients with chronic pulmonary thromboemboli. Circulation 1994;90:706–712.[Abstract/Free Full Text]
  32. Olman MA, Marsh JJ, Lang IM, Moser KM, Binder BR, Schleef RR. Endogenous fibrinolytic system in chronic large-vessel thromboembolic pulmonary hypertension. Circulation 1992;86:1241–1248.[Abstract/Free Full Text]
  33. Benotti JR, Ockene IS, Alpert JS, Dalen JE. The clinical profile of unresolved pulmonary embolism. Chest 1983;84:669–678.[Abstract/Free Full Text]
  34. Torbicki A, van Beek EJR, Charbonnier B, Meyer G, Morpurgo M, Palla A, Terrier A, Galie N, Gorge G, Herold C, et al. for Task Force on Pulmonary Embolism, European Society of Cardiology (ESC). Guidelines on diagnosis and management of acute pulmonary embolism. Eur Heart J 2000;21:1301–1336.[Free Full Text]
  35. Bonderman D, Turecek PL, Jakowitsch J, Weltermann A, Adlbrecht C, Schneider B, Kneussl M, Rubin LJ, Kyrle PA, Klepetko W, et al. High prevalence of elevated clotting factor VIII in chronic thromboembolic pulmonary hypertension. Thromb Haemost 2003;90:372–376.[Medline]
  36. Kimura H, Okada O, Tanabe N, Tanaka Y, Terai M, Takiguchi Y, Masuda M, Nakajima N, Hiroshima K, Inadera H, et al. Plasma monocyte chemoattractant protein-1 and pulmonary vascular resistance in chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med 2001;164:319–324.[Abstract/Free Full Text]
  37. Kim H, Yung GL, Marsh JJ, Konopka RG, Pedersen CA, Chiles PG, Morris TA, Channick RN. Endothelin mediates pulmonary vascular remodelling in a canine model of chronic embolic pulmonary hypertension. Eur Respir J 2000;15:640–648.[Abstract]
  38. Bauer M, Wilkens H, Langer F, Schneider SO, Lausberg H, Schafers HJ. Selective upregulation of endothelin B receptor gene expression in severe pulmonary hypertension. Circulation 2002;105:1034–1036.[Abstract/Free Full Text]
  39. Reesink HJ, Lutter R, Kloek JJ, Jansen HM, Bresser P. Hemodynamic correlates of endothelin-1 in chronic thromboembolic pulmonary hypertension. Eur Respir J 2004;24:110s.
  40. Coulden R. State of the art imaging techniques in chronic thromboembolic pulmonary hypertension. Proc Am Thorac Soc 2006;3:577–583.[Abstract/Free Full Text]
  41. Kafi SA, Melot C, Vachiery JL, Brimioulle S, Naeije R. Partitioning of pulmonary vascular resistance in primary pulmonary hypertension. J Am Coll Cardiol 1998;31:1372–1376.[Abstract/Free Full Text]
  42. Fesler P, Pagnamenta A, Vachiery JL, Brimioulle S, Abdel Kafi S, Boonstra A, Delcroix M, Channick RN, Rubin LJ, Naeije R. Single arterial occlusion to locate resistance in patients with pulmonary hypertension. Eur Respir J 2003;21:31–36.[Abstract/Free Full Text]
  43. Kim NH, Fesler P, Channick RN, Knowlton KU, Ben-Yehuda O, Lee SH, Naeije R, Rubin LJ. Preoperative partitioning of pulmonary vascular resistance correlates with early outcome after thromboendarterectomy for chronic thromboembolic pulmonary hypertension. Circulation 2004;109:18–22.[Abstract/Free Full Text]
  44. Bresser P, Pepke-Zaba J, Jais X, Humbert M, Hoeper MM. Medical therapies for chronic thromboembolic pulmonary hypertension: an evolving treatment paradigm. Proc Am Thorac Soc 2006.
  45. Rubin L, Hoeper M, Klepetko W, Galiè N, Lang I, Simonneau G. Current and future management of chronic thromboembolic pulmonary hypertension: from diagnosis to treatment responses. Proc Am Thorac Soc 2006.
  46. Nagaya N, Sasaki N, Ando M, Ogino H, Sakamaki F, Kyotani S, Nakanishi N. Prostacyclin therapy before pulmonary thromboendarterectomy in patients with chronic thromboembolic pulmonary hypertension. Chest 2003;123:338–343.[Abstract/Free Full Text]
  47. Galie N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, Fleming T, Parpia T, Burgess G, Branzi A, et al. Sildenafil for long-term treatment of nonoperable chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med 2003;167:1139–1141.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 ChestHome page
C. Kearon, S. R. Kahn, G. Agnelli, S. Goldhaber, G. E. Raskob, and A. J. Comerota
Antithrombotic Therapy for Venous Thromboembolic Disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Chest, June 1, 2008; 133(6_suppl): 454S - 545S.
[Abstract] [Full Text] [PDF]

Home page
 Proc Am Thorac SocHome page
V. F. Tapson and M. Humbert
Incidence and Prevalence of Chronic Thromboembolic Pulmonary Hypertension: From Acute to Chronic Pulmonary Embolism
Proceedings of the ATS, September 1, 2006; 3(7): 564 - 567.
[Abstract] [Full Text] [PDF]

Home page
 Proc Am Thorac SocHome page
P. Bresser, J. Pepke-Zaba, X. Jais, M. Humbert, and M. M. Hoeper
Medical Therapies for Chronic Thromboembolic Pulmonary Hypertension: An Evolving Treatment Paradigm
Proceedings of the ATS, September 1, 2006; 3(7): 594 - 600.
[Abstract] [Full Text] [PDF]

Home page
 Proc Am Thorac SocHome page
L. J. Rubin, M. M. Hoeper, W. Klepetko, N. Galie, I. M. Lang, and G. Simonneau
Current and Future Management of Chronic Thromboembolic Pulmonary Hypertension: From Diagnosis to Treatment Responses
Proceedings of the ATS, September 1, 2006; 3(7): 601 - 607.
[Abstract] [Full Text] [PDF]

Home page
 Proc Am Thorac SocHome page
A. Peacock, G. Simonneau, and L. Rubin
Controversies, Uncertainties and Future Research on the Treatment of Chronic Thromboembolic Pulmonary Hypertension
Proceedings of the ATS, September 1, 2006; 3(7): 608 - 614.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Galiè, N.
Right arrow Articles by Kim, N. H. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Galiè, N.
Right arrow Articles by Kim, N. H. S.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS